ArticleBrain : a journal of neurology2026
Medial temporal ageing-related tau astrogliopathy below 66 years is associated with neurodegeneration.
Article in Brain : a journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
Ageing-related tau astrogliopathy (ARTAG) refers to aggregates of pathological tau protein in astroglial cells in the brain. Thorny astrocytes at the level of the glia limitans and/or white matter and granular/fuzzy astrocytes in the grey matter are characteristic for ARTAG, which is correlated with ageing. However, also rare cases with ARTAG below the age of 66 years have been reported. We studied a cohort of 157 brains from donors deceased between 48 and 65 years of age received from the Leuven neuropathological research group and Netherlands Brain Bank in order to gain insight into ARTAG in the medial temporal lobe at younger age and to find underlying correlates that might be obscured by age-related co-pathologies in older cohorts. Analyses were also performed on two comparison cohorts (Leuven, 268 cases; and Netherlands, 397 cases), with ages ranging from 66 to 99 years. Twenty-six of 157 cases (16.6%) between 48 and 65 years of age had ARTAG, mostly restricted to the medial temporal lobe. Only six cases exhibited ARTAG in lobar regions. ARTAG was found in all five previously described morphologies and locations: subpial, subependymal, perivascular, white matter and grey matter. In our young cohort, a significant correlation was found between ARTAG and the presence of neurodegenerative conditions of any kind and between ARTAG and age. When correcting for age and sex, the association between ARTAG and the presence of neurodegenerative conditions was upheld. There were no significant associations between ARTAG and specific proteinopathies, although trends were observed for α-synucleinopathy, tauopathy and TDP-43 proteinopathy diagnoses. The presence of lobar ARTAG was related to ARTAG severity in the young cohort. In the older cohorts, only age was significantly associated with ARTAG. These results suggest a link between ARTAG in the medial temporal lobe of young individuals and pathological protein aggregation of any kind in the brain independent of age and might lead us to question whether ARTAG points to astrocytes as important players for selective vulnerability for the aggregation of pathological proteins in distinct brain regions in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.